MenABCW-135Y possesses blockbuster potential as a replacement for standalone MenACWY and MenB vaccination in US adolescents.
By Michael Haydock, Lead Analyst
17 June 2016
I am the Lead Analyst of the immunology and inflammation and infectious diseases and vaccines teams at Datamonitor Healt...
Read full bio
Following its anticipated US launch in 2021, GlaxoSmithKline’s MenABCW-135Y (pentavalent meningococcal conjugate vaccine) would be the first vaccine on the market to cover serotypes A, B, C, W, and Y, positioning it well to replace the standalone meningococcal ACWY (MenACWY) and meningococcal B (MenB) vaccines currently recommended for use in adolescents. These serotypes account for the majority of meningococcal disease cases, with US surveillance statistics showing that serogroup B causes approximately 60% of cases among children below five years old, and serogroups C, Y, or W cause approximately two out of every three cases among persons aged ≥11 years. Currently, adolescents in the US are recommended to receive a primary dose of MenACWY vaccine at age 11 years, followed by a booster dose at age 16 years. Adolescents may also receive MenB vaccination from the age of 16 years in a two or three-dose schedule, necessitating a minimum of four separate physician visits to gain protection against all five major disease-causing serotypes. Conversely, MenABCW-135Y has the potential to provide protection against all five serogroups in a more convenient two-dose schedule, simplifying the immunization schedule for physicians and patients and potentially rendering separate vaccinations obsolete.
Datamonitor Healthcare believes that MenABCW-135Y could rapidly achieve blockbuster sales in the US market, although its ability to replace its predecessors will be highly dependent on it displaying non-inferior immunogenicity when compared to standalone vaccines in Phase III studies, as well as its price. Datamonitor Healthcare recommends that GlaxoSmithKline price the vaccine so that the cost of vaccinating persons aged ≥10 years is only slightly higher than the cost of vaccination with MenACWY and MenB vaccines separately. Payers are expected to be willing to tolerate a small increase in vaccine procurement costs if the pentavalent vaccine offers reductions in physician costs and/or superior vaccination coverage due to the resulting simplification of the immunization schedule.
MenABCW-135Y US sales for meningococcal vaccination ($m), 2021–25
|Source: Datamonitor Healthcare’s meningococcal vaccines forecast, June 2016|
Datamonitor Healthcare’s meningococcal vaccines: forecast also explores the impact of recent changes to vaccination recommendations and anticipated increases in vaccination coverage rates on the market value during 2016−25.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>